0000950170-23-052428.txt : 20231006 0000950170-23-052428.hdr.sgml : 20231006 20231006170009 ACCESSION NUMBER: 0000950170-23-052428 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20231002 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers FILED AS OF DATE: 20231006 DATE AS OF CHANGE: 20231006 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Tracon Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001394319 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 342037594 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36818 FILM NUMBER: 231314793 BUSINESS ADDRESS: STREET 1: 4350 LA JOLLA VILLAGE DRIVE STREET 2: SUITE 800 CITY: San Diego STATE: CA ZIP: 92122 BUSINESS PHONE: 858-550-0780 MAIL ADDRESS: STREET 1: 4350 LA JOLLA VILLAGE DRIVE STREET 2: SUITE 800 CITY: San Diego STATE: CA ZIP: 92122 FORMER COMPANY: FORMER CONFORMED NAME: Tracon Pharmaceuticals Inc DATE OF NAME CHANGE: 20070324 8-K 1 tcon-20231002.htm 8-K 8-K
false000139431900013943192023-10-022023-10-02

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 02, 2023

 

 

Tracon Pharmaceuticals, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-36818

34-2037594

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

4350 La Jolla Village Drive, Suite 800

 

San Diego, California

 

92122

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: (858) 550-0780

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, par value $0.001 per share

 

TCON

 

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On October 2, 2023, Bonne Adams notified TRACON Pharmaceuticals, Inc. (the “Company”) that she will be resigning from her position as Chief Operating Officer of the Company, effective October 15, 2023, through which time Ms. Adams will assist with an orderly transition of her duties. Ms. Adams’ resignation is not a result of any disagreement with the Company, and she has agreed to serve as a consultant to the Company following her resignation.

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

 

 

 

 

 

Date:

October 6, 2023

By:

/s/ Charles P. Theuer, M.D., Ph.D.

 

 

 

Charles P. Theuer, M.D., Ph.D.
President and Chief Executive Officer

 

 EX-101.PRE 2 tcon-20231002_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT EX-101.LAB 3 tcon-20231002_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Cover [Abstract] Amendment Flag City Area Code Document Period End Date Document Type Entity Address, Address Line One Entity Address, City or Town Entity Address, Postal Zip Code Entity Address, State or Province Entity Central Index Key Entity Emerging Growth Company Securities Act File Number Entity Incorporation, State or Country Code Entity Registrant Name Entity Tax Identification Number Local Phone Number Pre-commencement Issuer Tender Offer Pre-commencement Tender Offer Title of 12(b) Security Security Exchange Name Soliciting Material Trading Symbol Written Communications EX-101.SCH 4 tcon-20231002.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 100000 - Document - Document And Entity Information link:presentationLink link:calculationLink link:definitionLink XML 5 R1.htm IDEA: XBRL DOCUMENT v3.23.3
Document And Entity Information
Oct. 02, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Oct. 02, 2023
Entity Registrant Name Tracon Pharmaceuticals, Inc.
Entity Central Index Key 0001394319
Entity Emerging Growth Company false
Securities Act File Number 001-36818
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 34-2037594
Entity Address, Address Line One 4350 La Jolla Village Drive, Suite 800
Entity Address, City or Town San Diego
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92122
City Area Code (858)
Local Phone Number 550-0780
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.001 per share
Trading Symbol TCON
Security Exchange Name NASDAQ
XML 6 tcon-20231002_htm.xml IDEA: XBRL DOCUMENT 0001394319 2023-10-02 2023-10-02 false 0001394319 8-K 2023-10-02 Tracon Pharmaceuticals, Inc. DE 001-36818 34-2037594 4350 La Jolla Village Drive, Suite 800 San Diego CA 92122 (858) 550-0780 false false false false Common Stock, par value $0.001 per share TCON NASDAQ false EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 10 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 1 22 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document And Entity Information Sheet http://www.traconpharma.com/20231002/taxonomy/role/DocumentDocumentAndEntityInformation Document And Entity Information Cover 1 false false All Reports Book All Reports tcon-20231002.htm tcon-20231002.xsd tcon-20231002_lab.xml tcon-20231002_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 12 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "tcon-20231002.htm": { "nsprefix": "tcon", "nsuri": "http://www.traconpharma.com/20231002", "dts": { "inline": { "local": [ "tcon-20231002.htm" ] }, "schema": { "local": [ "tcon-20231002.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "tcon-20231002_lab.xml" ] }, "presentationLink": { "local": [ "tcon-20231002_pre.xml" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 23, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 22 }, "report": { "R1": { "role": "http://www.traconpharma.com/20231002/taxonomy/role/DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document And Entity Information", "shortName": "Document And Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "C_7c146b77-8589-4e7e-a224-f6da832d67cc", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "tcon-20231002.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_7c146b77-8589-4e7e-a224-f6da832d67cc", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "tcon-20231002.htm", "first": true, "unique": true } } }, "tag": { "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.traconpharma.com/20231002/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.traconpharma.com/20231002/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.traconpharma.com/20231002/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.traconpharma.com/20231002/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.traconpharma.com/20231002/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://www.traconpharma.com/20231002/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.traconpharma.com/20231002/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.traconpharma.com/20231002/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.traconpharma.com/20231002/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.traconpharma.com/20231002/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.traconpharma.com/20231002/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://www.traconpharma.com/20231002/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.traconpharma.com/20231002/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.traconpharma.com/20231002/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.traconpharma.com/20231002/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.traconpharma.com/20231002/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.traconpharma.com/20231002/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Securities Act File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.traconpharma.com/20231002/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.traconpharma.com/20231002/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.traconpharma.com/20231002/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.traconpharma.com/20231002/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.traconpharma.com/20231002/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 13 0000950170-23-052428-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-23-052428-xbrl.zip M4$L#!!0 ( .(1E13*[4_?+EBS)1-6.G9$= M(/?7WR/9AB2$!CH!#!T^ +:/7D?GK2-I]Q_7HP1=I;]=\/H&L9MJ6P\E>)B6* M^A&I0M!R MFO(DF:+/(B4I%21!_;K);>@C;:/])$'GJE2.SGG.Y25G;57E3[O# G !^$CS MO=9,OZ_L=B8O.F88AIUK!=,J@;K7D4R8N(%5CQK2,@RO4WZ< RV6@KHE:#$+ M*N8Z, MM=P")!0R-U_" ]J_? %>?(Y+?@%_?@9\;G_I:@XKK^^HU53?4?*OI MKL'3+#V!:9>"+B_&"MDIIF/> 4"SGG+8OLLL.?.@H>K@=28'AVUP3->SM0#J%)&D>9W*DB5&-T\5&@&USII[E M8_M6)9:%#0N;7EU)016KS=0")>#5>$B@C.8+U773,*S6IY_0[I 3!G_1;B&* MA'\*\&^[G?)?]7+$"Z*9#/,_)^)RK]7+T@)8#P\ TRU$RZ>]5L&OBTY)O!U5 M:Z>J=C?*V!3EQ33A>ZT1D1T@<2;*_U^;\19T% ;0N'/(RQ M8P"J0\^.L$]--R!N;(=QV$(I&:E6N.CN@TQA2JY\3LA%-;;KXIS',.K_0B'' MBWP?!VX08H?['!/+2)$_\>GW==( JK=#QS;#.SWM MS*-4\IA+D-<\_[2K.+>;:T:!UI#FY*[BM[U6#G.9**[1[X92=491(:X)K7V= M,YBZSGP=97.S;>C'/)M(_:0E5;<:H4;;8T=8%>4:9_638.HY%EPBW06^E%U[ M1[_-8VBQ\*?ZU7SM8T!@QNHGD".R4,KFTXVNL>IRM]]NNLGN :V_U,]U(YTY MU-1XO$%<9X9'.L!*FJ7&-4-%F80ON,C&7:MMN>,"L6P2)1Q],/3/CJH39*$: M<=?8B:$1G(O_XUW3&!<[)0_KTM6WF(Q$,NT.Q(CG6H&?9R.2UH!15A39J%O5 M2A)QD783'A>*E?,Q2>M>70U%P3&\H;P[EAQ?23)>;'NVN;\MM/>W;="U(MX9 M09M7@A7#;BP*7,DG:.SG#Z9G[.QV5)N E?$\3AX[9+?MNPL=><*X*53/Y>+( M:99DLELC_WX\7'%E572C+&&S/0Q61,SO)T>#PP/4'^P/#ON[D03YW3_L_7Y^ M-#@Z[*/]DP-T^$?OG_LGOQZBWNGQ\5&_?W1Z4L+5V%SC:*P51_.?_?X_CTY^ M'9R>;*.#=J\-9IOKA/=->S57BAZ[CO'79Z+\BN'J9TU"""Q5P6Y8KBJBKX6^XBR&!5#KCY-I"@$ M5'UX38 J;J,^FZ'M+."U(,J\G#<_U9B4TP9LI^P9 M> YMX*.J " F(>.<=W,^)A*LXM)5A-IE7?6ER$4D$K#*NS5T!010[(;QZLK_ MJG#?*5A9#3C6B_4-2QSK6;];3^6VEM*D;9@BW;F"KN)(D!VYUR%$]!6 M_$@\+Q"_5)%"J3]S]K'[D/Y^;(?NT=\FL=R(61'V../8B6T?DYC;V/== M:EDLCLTX6I?^/M/NX&'I)+90&13::XGKHLO@#1Y!*T-5##,RQ5- ">9ILZ;O ME!99!!ZY86WK".O#VO\.Q\)?)4'68Q8\U;O[80V#']'Y7[40EQ(:6-185>J4$E(-^43K6"K=9DGNA6/I0F[6?:QWUXDTJ?B<.OPFH AIZ:]5*OU M=".2H_Z84Q4$94BDZ*C(40]0#8/XN&[O[*ENQT8,OUDQW$3GP)KW#99X#P]\ M?[B"X $ Q_Q>]P1&IQ"\U[);[\A5>8(R7=6$#P(OLIEG8^ZH=QF;-^C5\K):.2KX6&:7 MJIZF6?('/"%71/(G6/#OS)M^01(UJ$M<9MG8V M&[FVYQ(S7@^]#T9S._O@FQ,R[G[=>-AJ)7.68(J6O M4"DS-I/3B,DY.N^CP]$XR:9.E6S K.9<_?,^OO%_?'FGS@?<8DS_/JSQ>1H, P MGAJ9N:%0ZX>BT(WT:.[KR]C/GC$5Q:,5^;&/"@P#FF08X-*B# M*;<\+XX-:MO!6FE#Q[E.Y9G,+H7>[_BF5IIZP+'0X520IL3^7U12-6+E_OGQ M6@[]?2L%;KF4<8/BV" ,.P8CF)B@&0S3M1T6AB'UU\OX9QEP=O*_8JP7F!O% MU:%E6M9F.>4]17XKHE-Y9&<2%(T8DP0=7G,Z42<\H-,X%I3G;R-,_VZ=@,9A M^MVS!8A?I.3O-Q<]EF:U_QBV15.S M>]99FF]>*RSQI.)FBZT#_.B.;:[!N+Z MV(D\%X>!3S!P+64V-6;I%HS@X_.%*MX<-;BN$P6QQV%F M/7!96&!AXA #4]OWB<PF?0$%RB$[TA2Z+JL7*MMY&(U2:L]((SU%>Q7/2%Y$6U M&WK]V[+:]F:#['/A:N%XB&4C?W7CHC?D]*L^ 8*,QS(;2Z$29J/L&D4\R:X4 M-:J/BDA1@']#,4AA,*!%CH2J@@&5%AG*Q6B2%"3EV21/IB@GAPX\7J M0$;7Q''H$!H%?N!Y*^]5^8\4!:!8Y0%/TBJO-+^[K!5E61(1()8"2':5@?[\ M(?0=9^DN19L.P:8U0]1S)Q?=D+0#AKV&_#&I MFENAS8A%L6MRD-94;7XUN(O#R/,CF]MF''NK4O69Y$I2JT-?]3%TRC"0IW$, MGOZ&NI>'!G/IREN]%ZC]*,\G7&YH?MTT;W/LJ'/Z'T/S%>Q=FG_F$P##%S@! M<&5=>FOJE3X7E^"UC9>="ZAE3.6# 8Z[;R#<9S]T[L9#)WN8[HH5.&[3SAU< M#-%8-R&:)H8G7YD]RAV, W5!0GG,(!TBFI \?_'(>UKPS ;AGD;#%-RRDEU!I_6,;PV9L'P@O[ FUOK M;,6]/4U*_GLSJ=LQC2/'P,?'C$',GHE'D4TZL<%5&KPRDTC1J&IJ# CJ.8V@2'CDW5 K2'(R^FBAOMF#O,9;Z[+E5=QQSUX=AW KO*B%O'CLIG M8/(A1R8K,BRKX[;HY2IN#5'T111G4 # M(_@*5CS7I\PM9+>('$'?.2#Y0JUG7LCLJABJ\/=89;R0'#$>B[0\@KMRW-[&8J,M)57\'9WL;L4[>M6^+@3- <6.U2'>*KVLC*5;$;8>>=7+GRCO$6GE]\A?VS.,V'/ >#)=!O+7 UD: MQQ8VPB *610%EKNFRPGJOO^JN]XK>_[ZZVL;RBKE8/P-R;8-\FRIF!1W\O^& M( 1YPFD!0C#-])+4).<:"C!091FJ6Y*%7J8J+TU51*#;2J:J\2L!32NR3J'W M\$7R2Y%#N?CF7F]"J3J+6P&K6Z$9D2PO\PO9?>MA]A:Y60^;E97MI^[)>)C2 M7N2Z@/F8W3V M\Q&$-2E0#A!7(DE0I#1-#@A1@[FHUA;0@ M3J:S:@W:4UUC$V6:MV_+UUM:JW&42?1"XPH1]7*2:$I5RH^)G%Q(7F;8Z+;F MA@!:3V-&*5P-5V;O9/53D%-M M4&GZ6EC_Z->3_<'OYX?]EZ29UVP" MPH:2B3*)M1-?WI^IF@$)J9@9/BBY LU$?$B26%GMJB*=?E^>]^[[W031V]L''V#UPU>WSM>G?;3+KTL MX1N+WXW@_5$)>8/7#5XW>&WRJ>--POY3U5[SHVL'X"1UWP3EOS_:K5[4+RB*JT:XH )'T6^F%T_8E\T[:[$1?/>4M=C=3I2QZ:>?=CO#8I1\^G]02P,$% M @ XA&5WK:03,- P L D !$ !T8V]N+3(P,C,Q,# R+GAS9+U6WV_: M,!!^WU_AY6G3YL0!,:E1Z=2-54)BW02KU+?). =8<^S,=@K\][.3F(86$-VD M/6'N[KOO?MJY_+@I!'H ;;B2PRB-281 ,I5SN1Q&=S-\/?L\'DA:"#3U M*(.F8$ _0!XW/CJA$9)(VR:\I/I.@&T[IAV:6X>5:2MH#IQ<5%4FNCJU<(U0/#BU)I MBYJYF2A6=^,$F?^' R/V(ISV<#^-G;,(R8,3=R3?;!,=Z#73V+T1R;'W_ _G"2\]G4O8STX%(D(*P)DI,A'-ZIQQ"HE,K6O%X4 MA&7)Y4(U$B?S'>QVYU@\HQ@?W:\.G$0$)/'\ +6Z_![ M+?,OTD6U';MAU"FSOSG6>8AS!!H#N[QY_6\N@B(?\.[7PF[HW.& M&F^HX^XR>>KDB?O*0/Y-7M7GI^5NP:W)"2"C@E7BY;C'L(["6F%H5[NSR9.E M;06=U6XDS45S]0=02P,$% @ XA&5SL?XW&A!0 !3( !4 !T8V]N M+3(P,C,Q,# R7VQA8BYX;6S-FVUOZC84Q]_W4YRQ-ZUV0T*[3BMJ>\5H>X76 M)Q6N=K5IN@J) >L&&SFAP+>?[<0I(4Y@4"=]U9 <__T[\4-\CMW+S\MI *^( MA9B2JT:KZ30 $8_ZF(RO&E_[5J??[?4:GZ^/+G^R++BYZSW"(UI QXOP*[K! MH1?0<,X0'/8A#28 M1[S"L.G1J0V6E(2#[L!]%6EGZ!'O"9T@@!>1*D0 M7E"(V"ORF[%FP#UH!\J-98C;H3=!4_>>>A+OJK'FSW+(@B9E8_O4<<[LM%2A MA?AE*3-+W+):I]99J[D,_0;PUB"AK'N'2I3Y,F>_.)/6K8N+"UL^34U#K#/D MLBW[V\-]7_II\1:*^%M#C>LC@.1UN$,4B*8%J==F-$ EB.*QG50L[2,.WT3)"Q$>^K#"MDGH9HT"\?LI4R0E#HY@@Y BR^A!YS3%]M7V$;=$- MQ(4E+L3+_9G_^-ZEO*]WAF'$7"]22A+JJI%_;IO&Z?#QX8LQX8PU.]KEQ MG"Z.5AT^!KO41[J7L_[8.(R:/IX1P]2_);Z8%#14>KO*\ 9WH*Z:5X1;)>/!^8&/3[3+_]$JT+*3;N*\&ZGB(WYNN<+ MHXMHTJ73F4N*(?76%:'>X0 ]SJ=#Q KYUDPJ@N*K*LIFE,DUDNQB73KG+;DJ M'3WEI2I"?T%C++[Y)'ITI\6L&V85P0W<9<_G0P*/<+S^W-+R1?;&<<7Z.'B> M4%+<-W,FQJ&>&>]04_XI]I#X'O?"<([80*PVV=-HI(7<6J1JZ/^%6REH'WES MQOM%(J>/2?)1!9JL/1V63QA+0)@?B72&HA8 M7_O9 )2OBNB<:5=.F9#P>S!,W\U.(;#0:5Q+#?A'J?Q[:;_5\GZDF6AQ3])4 M X2(&<[U.'+?%\HE0&B $#&#J0TL]^1-0R2RZ"ST.!A889RL) M=$_D6 \2I4_J0B0D$3R1*KQXBU3?R0?9SRD#(5D!?R:&?2<78DW@H@;':EEX M^TY^2%71%DK7I"<;(?!A+B1B(-6 RYDDU\;%A_$K28@U(1$UZ<5;]+PG>K*X MQ"@4>R4@]" 6-(E=&DP?U@@9Z;71D%1@?&QG8^_#?'G3 B%F$KL@&#^,GXM" M5M5HW]H,VO>$ES(@=8SB;@O?]\3GLI:WI@NQ,,3*(*4K<OT>'@"2M4L\WJ"X+#/ ?^6)5H&)YY\\F!?Z%0(E)(9XDQJ8=^>$6M M+&*&4YMKV),WT8*L6"EWAV73+"[S5,7\*C'L2MV_&*MSP%\@'@\YOT6O2-O,<' -=NW6O9\SF/#X!?L*&O=4"7[JC3 MA8)M_BR[+L%1)W3IYG\6O3C#4:<#^2,!6>J-C$:=J#L=%,C2;T]LU.F0_OA MU@--_J).Y"V'"K+L94F,>IPH.FJ@N+4IBWI0=SV H-!W2E]\"%=V=^)CX!<= M5E#0VAQ%O:BZ(PR;N+GT1$W(A0<;4F!]8J(>7.UQ!T6:3TC4 UEZ"$+!%F!T(()- ^)-KTA4!\;)_C>Z_M>\7- MISA@:$6DHH+W#*=E&XAP3_B4SWO&E['9'P^&0^/3[=7-;Z:)[AZ&S^B9K%'? MB^B*W%'E,:&6DJ WXZ>WZ.M?HT?T2/GW*58$W0EO&1 >(1,MHBCL6M9ZO6[Y M,\J58,L()E0M3P06,LW=\ -)L'Z/[G!$4->UW;;IV*;=F3CONQVGV[%;]@>W M\X=M=VW[H)L(-Y+.%Q%ZX[U%NA?,S3EA;(,>*,?ZBB14 8 MUK&^/CV.$YTF6"B"52/&[15"V^60@I$1F2']_#(:Y@:))/8$#Q=8!CBQJ#:! M8]NN%>%8O]2S'%/*421P1 M[A,_,4+*F@DO!V+:)87,KYIFKX!^XC6*>*VY6%D^H0EU_259TF0YX<>W@8#X M[T^55AJE(S$\):QGG+9;5=/IP^KY>@4?&)X7T,FW5TYG ";LP[XT$#XI6IS# MYLK)I,[U2B05X%^^WB@+6!7C:J,W@1'/L$J:*R>SC;Z^[T.4J=T#HHPX!3G)8G1-5!\H M(\_+8$ID*;\#2$VDX*8I9"ADR2]8O@Q?.5V=,[#7A>#EOGD"J9S4JP2'"N H]H@^ MCX=*+8F[%(WZ9^B6RO1,?&6$GS.<:<3?=$OH'<"J8W4?>PM M,)^3DI@NA%5/3C#JT0A.CB?8ZR1DZT743D&5$YM(K"LAXTTP%46<\NV5T_D' M3 -)H?;L)=]M9*J 5C$N1^\P]^S+/%4LO710^'J2$>>+$3N$%6()XYG>@C(_ M[3V3(BC*(=/91%%&AX2$6.T9D&,[MJY'A9##:)_L&:Z!E@K(B%#3/G: _Y.D M?-:X5^2T&ZNH)/7,C.4V7MHV;1=_QKR#G/F+-!^$=L=9=N9 MON9&V_DD/5/8W,V_)+//(N_/ADLKJ0ID CL-%WA82\A4O6^XJ@O%B$SHAX8+ M/2Y=9,J:>_^Z4/?()'YLK,336DEV&C1WR[Q<;,E4-O=*=JXZD^EKKF^>%G7V MJMSFWE2*JT)[9>WF1EU122GSP^8><$<5J$0 V*( !$ M ( ! '1C;VXM,C R,S$P,#(N:'1M4$L! A0#% @ XA& M5WK:03,- P L D !$ ( !C1$ '1C;VXM,C R,S$P,#(N M>'-D4$L! A0#% @ XA&5SL?XW&A!0 !3( !4 ( ! MR10 '1C;VXM,C R,S$P,#)?;&%B+GAM;%!+ 0(4 Q0 ( .(1E=XC>0R MA@0 /0D 5 " 9T: !T8V]N+3(P,C,Q,# R7W!R92YX 8;6Q02P4& 0 ! $ 0 5A\ end